 |
8 Diseases |  |
1 Trial |
|
1 Trial |  |
107 News |  |
| 12» |
- | Zafatek (trelagliptin) / Takeda, Trulicity (dulaglutide) / Eli Lilly
Journal: Effects of dulaglutide and trelagliptin on beta-cell function in patients with type 2 diabetes: a randomized controlled study: DUET-beta study. (Pubmed Central) - Aug 5, 2024
levels compared to trelagliptin and body fat mass was reduced without loss of skeletal muscle mass (UMIN-CTR 000024164). The online version contains supplementary material available at 10.1007/s13340-024-00717-6.
- | Zafatek (trelagliptin) / Takeda
Preclinical, Journal: Trelagliptin relieved cognitive impairment of diabetes mellitus rats: Involvement of PI3K/Akt/GSK-3? and inflammation pathway. (Pubmed Central) - Nov 3, 2023
In conclusion, trelagliptin improved the cognitive lesion in DM rats by suppressing the activation of the inflammatory route and by activating the PI3K/Akt/GSK-3? pathway at the same time, as well as interacting with the pathways that protect neurons, which still need further research.
- | Zafatek (trelagliptin) / Takeda, Remozen (remogliflozin etabonate) / Islet Sci
Biomarker, Preclinical, Journal, Combination therapy: Impacts of trelagliptin and remogliflozin alone and in combination with Alpha Lipoic Acid on cardiac function in streptozotocin-induced diabetes mellitus (Pubmed Central) - Nov 1, 2023
The combination of trelagliptin, remogliflozin, and ALA may have additional clinical value in managing DCM by targeting oxidative stress, inflammation, and glucotoxicity. However, further research is needed to validate these findings and explore their potential clinical applications.
- || Zafatek (trelagliptin) / Takeda, Januvia (sitagliptin) / Merck (MSD)
Review, Journal, Gram positive: Computational tools for exploring peptide-membrane interactions in gram-positive bacteria. (Pubmed Central) - Mar 25, 2023
Herein, we present a comprehensive survey of diverse computational approaches that are suitable for detecting QSPs and QS interference molecules. This review highlights the utility of these methods for developing potential biomarkers against infectious Gram-positive pathogens.
- ||| Zafatek (trelagliptin) / Takeda
Trial completion: Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Severe Renal Impairment or End-stage Renal Disease" (clinicaltrials.gov) - Feb 10, 2023
P=N/A, N=87, Completed, Sponsor: Takeda
This review highlights the utility of these methods for developing potential biomarkers against infectious Gram-positive pathogens. Active, not recruiting --> Completed
- ||| Journal, Adverse events: Comparison of Adverse Events Occurred During Administration of Dipeptidyl Peptidase-4 Inhibitor in Patients with Diabetes Using FDA Adverse Event Reporting System. (Pubmed Central) - Jan 14, 2023
Although it is impossible to select a DPP-4 inhibitor with aROR of < 1.000 of all occurrences of adverse events, these results may be used for drug selection when the patient has adverse events that need to be avoided. We provided the sample code of software R that can reproduce the results.
- || Zafatek (trelagliptin) / Takeda
Trial completion date, Trial primary completion date: Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Severe Renal Impairment or End-stage Renal Disease" (clinicaltrials.gov) - Oct 31, 2022
P=N/A, N=87, Active, not recruiting, Sponsor: Takeda
We provided the sample code of software R that can reproduce the results. Trial completion date: Oct 2022 --> Jan 2023 | Trial primary completion date: Oct 2022 --> Jan 2023
- || Zafatek (trelagliptin) / Takeda, Marizev (omarigliptin) / Merck (MSD)
PK/PD data, Journal: Prediction of pharmacokinetics and pharmacodynamics of trelagliptin and omarigliptin in healthy humans and in patients with renal impairment using physiologically based pharmacokinetic combined DPP-4 occupancy modeling. (Pubmed Central) - Sep 18, 2022
Trial completion date: Oct 2022 --> Jan 2023 | Trial primary completion date: Oct 2022 --> Jan 2023 The present PBPK-DO model can simultaneously predict PK and PD of TRE and OMA in humans and also provide valuable recommendations for dosing adjustment in renal impairment patients, which cannot be achieved by alone depending on PK change.
- | Zafatek (trelagliptin) / Takeda, MG132 / Jilin University, Dorothy M. Davis Heart and Lung Research Institute
Journal: ABCC8-Related Maturity-Onset Diabetes of the Young: Clinical Features and Genetic Analysis of One Case. (Pubmed Central) - Jul 28, 2022
The diagnosis of maturity-onset diabetes of the young (MODY)12 was confirmed in our patient. The ABCC8 variant inhibited both ubiquitination and autophagy lysosome degradation pathways, especially the ubiquitination degradation pathway.
- | Zafatek (trelagliptin) / Takeda
Retrospective data, Journal: Safety and efficacy of once weekly dipeptidyl-peptidase-4 inhibitor trelagliptin in type-2 diabetes: A meta-analysis. (Pubmed Central) - May 4, 2022
The ABCC8 variant inhibited both ubiquitination and autophagy lysosome degradation pathways, especially the ubiquitination degradation pathway. Once weekly trelagliptin has good glycaemic efficacy and well tolerated in people with T2DM.
- || Retrospective data, Review: Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis. (Pubmed Central) - Feb 16, 2022
Specifically, trelagliptin raised the risk of fracture, whereas voglibose and albiglutide showed benefit with statistical difference...Some drugs (omarigliptin, sitagliptin, vildagliptin, saxagliptin, empagliflozin, ertugliflozin, rosiglitazone, pioglitazone, and nateglinide) may increase the risk of fracture, while others (such as dulaglutide, exenatide, liraglutide, semaglutide, lixisenatide, linagliptin, alogliptin, canagliflozin, dapagliflozin, glipizide, gliclazide, glibenclamide, glimepiride, metformin, and insulin) may show benefits...When developing individualized treatment strategies, the clinical efficacy of anti-diabetic drugs must be weighed against their benefits and risks brought about by individual differences of patients. This Systematic Review was prospectively registered on the PROSPERO (https://www.crd.york.ac.uk/PROSPERO/, registration number CRD42020189464).
- | Zafatek (trelagliptin) / Takeda
Journal: Trelagliptin ameliorates oxygen-glucose deprivation/reperfusion (OGD/R)-induced mitochondrial dysfunction and metabolic disturbance of endothelial cells. (Pubmed Central) - Jan 27, 2022
After co-administration of the inhibitor of the AMPK pathway, the effects of Trelagliptin on mitochondrial function and metabolic alterations were significantly abolished. Taken together, our data indicate that Trelagliptin ameliorated OGD/R-induced mitochondrial disturbance and metabolic changes by activating the AMPK pathway.
- | Zafatek (trelagliptin) / Takeda
Preclinical, Journal: Trelagliptin Alleviates Lipopolysaccharide (LPS)-Induced Inflammation and Oxidative Stress in Acute Lung Injury Mice. (Pubmed Central) - Dec 25, 2021
The TLR4/NF-κB signaling pathway was activated and oxidative stress was induced by stimulation with LPS; however, both effects were suppressed by the administration of Trelagliptin. Trelagliptin might alleviate LPS-induced inflammation and oxidative stress in acute lung injury mice.
- | Zafatek (trelagliptin) / Takeda
Journal: Trelagliptin ameliorates IL-1β-impaired chondrocyte function via the AMPK/SOX-9 pathway. (Pubmed Central) - Dec 25, 2021
Collectively, our study demonstrates that the DPP-4 inhibitor Trelagliptin has a protective effect on chondrocyte function. Trelagliptin may have the potential role to antagonize chondrocyte-derived inflammation in OA.
- || Zafatek (trelagliptin) / Takeda
Clinical, PK/PD data, Journal: Investigation of Pharmacokinetic Parameters of Trelagliptin in Egyptian Volunteers Using Sensitive LC-MS/MS: A Comparative Study with a Japanese Population. (Pubmed Central) - Dec 21, 2021
The proposed method was successfully applied to a pharmacokinetic study conducted on Egyptian volunteers. No dose modification is required upon comparing the pharmacokinetic parameters of the current study and previous studies on non-Egyptian volunteers.
- | Zafatek (trelagliptin) / Takeda
Journal: Trelagliptin stimulates osteoblastic differentiation by increasing runt-related transcription factor 2 (RUNX2): a therapeutic implication in osteoporosis. (Pubmed Central) - Nov 21, 2021
Blockage of AMPK with compound C abolished the effects of Trelagliptin in RUNX2 and osteoblastic differentiation, suggesting the involvement of AMPK. Our findings suggest that Trelagliptin might possess a potential for the treatment of osteoporosis.
- ||| Zafatek (trelagliptin) / Takeda
Trial completion: Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus" (clinicaltrials.gov) - Nov 9, 2021
P=N/A, N=3198, Completed, Sponsor: Takeda
Our findings suggest that Trelagliptin might possess a potential for the treatment of osteoporosis. Active, not recruiting --> Completed
- || Zafatek (trelagliptin) / Takeda
Enrollment closed: Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Severe Renal Impairment or End-stage Renal Disease" (clinicaltrials.gov) - Oct 19, 2021
P=N/A, N=87, Active, not recruiting, Sponsor: Takeda
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Retrospective data, Review, Journal: Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials. (Pubmed Central) - Sep 29, 2021
As a class, DPP4i are not associated with any increase or reduction of MACE, all-cause mortality, and heart failure. Saxagliptin seems to be associated with an increased risk of hospitalization for heart failure.
- | Zafatek (trelagliptin) / Takeda
Preclinical, Journal: Trelagliptin Mitigates Macrophage Infiltration by Preventing the Breakdown of the Blood-Brain Barrier in the Brain of Middle Cerebral Artery Occlusion Mice. (Pubmed Central) - Sep 26, 2021
In an in vitro hypoxia model of endothelial cells, the increased migration of macrophages, enlarged permeability of endothelial monolayer, downregulation of ZO-1, and elevated expression level of CXCL1 by hypoxic conditions were all reversed by treatment with Trelagliptin in a dose-dependent manner. Our results demonstrate that Trelagliptin might mitigate macrophage infiltration by preventing the breakdown of the blood-brain barrier in the brains of MCAO mice.
- | Zafatek (trelagliptin) / Takeda
Journal: The anti-diabetic drug trelagliptin induces vasodilation via activation of Kv channels and SERCA pumps. (Pubmed Central) - Sep 15, 2021
From these results, we concluded that the vasodilatory effect of trelagliptin was associated with the activation of Kv channels (primary the Kv7.X subtype) and SERCA pump regardless of other K channels, Ca channels, cAMP/PKA-related or cGMP/PKG-related signaling pathways, and the endothelium. Therefore, caution is required when prescribing trelagliptin to the patients with hypotension and diabetes.
- | Zafatek (trelagliptin) / Takeda
Preclinical, Journal: The protective effects of trelagliptin on high-fat diet-induced nonalcoholic fatty liver disease in mice. (Pubmed Central) - Jul 29, 2021
Mechanistically, we found that the administration of trelagliptin reduced the activity of hepatic nuclear factor-κB but increased the activity of AMP-activated protein kinase. These findings suggest that trelagliptin might become a promising therapeutic agent for the treatment of NAFLD.
- | Retrospective data, Journal: Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials. (Pubmed Central) - Jun 22, 2021
In conclusion, available data from randomized controlled trials seem to confirm the association between DPP-4 inhibitors and bullous pemphigoid. This association could be limited to one molecule of the class (i.e., linagliptin), although data on other DPP4-i (e.g., vildagliptin) are insufficient to rule out similar detrimental effects.
- | Nesina (alogliptin) / Takeda, Zafatek (trelagliptin) / Takeda
Journal: Structural optimization of pyrazolo[1,5-a]pyrimidine derivatives as potent and highly selective DPP-4 inhibitors. (Pubmed Central) - May 27, 2021
The interactive mode in this case resembles that of Alogliptin and Trelagliptin. Further in vivo IPGTT assays in diabetic mice demonstrated that c24 effectively reduces glucose excursion by 48% at the dose of 10 mg/kg, suggesting that c24 is worthy of further development as a potent anti-diabetes agent.
- | Zafatek (trelagliptin) / Takeda
Journal: The dipeptidyl peptidase (DPP)-4 inhibitor trelagliptin inhibits IL-1β-induced endothelial inflammation and monocytes attachment. (Pubmed Central) - May 26, 2021
Mechanistically, trelagliptin suppressed the activation of activator protein-1 (AP-1) and NF-κB signaling pathways, which modulate the inflammatory process and monocyte adhesion. Collectively, our results showed that trelagliptin had a powerful inhibitory effect on the attachment of monocytes to endothelial cells, indicating that trelagliptin might have a protective effect on cardiovascular diseases such as atherosclerosis.
- | Nesina (alogliptin) / Takeda, Zafatek (trelagliptin) / Takeda, Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Journal: Preparation of (R)-3-aminopiperidine by resolution with optically active cyclic phosphoric acids. (Pubmed Central) - May 5, 2021
(R)-3-aminopiperidine ((R)-APD), a key intermediate for alogliptin, trelagliptin, and linagliptin, was successfully resolved from racemic 3-aminopiperidine with an enantiomerically pure resolving agent, namely, (R)-4-(2-chlohydroxy-1.3.2-dioxaphosphorinane 2-oxide ((R)-CPA), via diastereomeric salt formation. By this resolution approach, (R)-3-aminopiperidine was obtained in 99.5% yield with 99.6%e.e.
- ||||||| Zafatek (trelagliptin) / Takeda
Trial completion, Trial completion date, Trial primary completion date, Monotherapy: Clinical Trial of Trelagliptin Succinate Tablets in the Treatment of Type 2 Diabetes (clinicaltrials.gov) - Jan 12, 2021
P3, N=254, Completed, Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
By this resolution approach, (R)-3-aminopiperidine was obtained in 99.5% yield with 99.6%e.e. Active, not recruiting --> Completed | Trial completion date: Jul 2021 --> Dec 2020 | Trial primary completion date: Jun 2021 --> Dec 2020
- | Zafatek (trelagliptin) / Takeda
Journal: Trelagliptin succinate: DPP-4 inhibitor to improve insulin resistance in adipocytes. (Pubmed Central) - Nov 28, 2020
In addition, the secretion of free fatty acids and resistin were decreased. In conclusion, our study suggested that trelagliptin succinate improved insulin resistance in adipocytes via regulation of PI-3K/AKT/GLUT4 insulin signaling pathway.
- ||| Zafatek (trelagliptin) / Takeda
Clinical, P3 data, Journal: Efficacy and safety of trelagliptin in Japanese patients with type 2 diabetes with severe renal impairment or end-stage renal disease: results from a randomized, phase 3 study. (Pubmed Central) - Nov 25, 2020
In conclusion, our study suggested that trelagliptin succinate improved insulin resistance in adipocytes via regulation of PI-3K/AKT/GLUT4 insulin signaling pathway. Once-weekly trelagliptin 25 mg was efficacious, with no major safety concerns, and represents a meaningful treatment option in this patient population.
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Januvia (sitagliptin) / Merck (MSD)
Journal: Association between dipeptidyl peptidase-4 inhibitor and aspiration pneumonia: disproportionality analysis using the spontaneous reporting system in Japan. (Pubmed Central) - Oct 2, 2020
This result suggests that DPP-4 inhibitors may affect the immune function associated with the development of aspiration pneumonia. Furthermore, there is a possibility that the amount of DPP-4-Is used clinically cannot increase the amount of substance P in sufficient quantity to prevent aspiration pneumonia.
- | Retrospective data, Journal: Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials. (Pubmed Central) - Aug 23, 2020
Furthermore, there is a possibility that the amount of DPP-4-Is used clinically cannot increase the amount of substance P in sufficient quantity to prevent aspiration pneumonia. Available data do not support the hypothesis of an association of DPP4i treatment with malignancies, with a possible beneficial effect for colon-rectal cancer.
- || Nesina (alogliptin) / Takeda
Clinical, Journal: Treatment preference for weekly versus daily DPP-4 inhibitors in patients with type 2 diabetes mellitus: outcomes from the TRINITY trial. (Pubmed Central) - Jul 11, 2020
P4
Patients expressed a significantly greater treatment preference for once-daily alogliptin than once-weekly trelagliptin, although patient satisfaction and HbA1c levels were similar across treatments. The decision to administer a once-weekly or once-daily DPP-4i is likely to depend on patient preference, patient-physician discussions, and treatment practices of the prescribing physician.
- ||||| Zafatek (trelagliptin) / Takeda
Enrollment closed, Monotherapy: Clinical Trial of Trelagliptin Succinate Tablets in the Treatment of Type 2 Diabetes (clinicaltrials.gov) - Jun 30, 2020
P3, N=254, Active, not recruiting, Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
The decision to administer a once-weekly or once-daily DPP-4i is likely to depend on patient preference, patient-physician discussions, and treatment practices of the prescribing physician. Recruiting --> Active, not recruiting
- || Zafatek (trelagliptin) / Takeda
PK/PD data, Journal: The Chiral Bioconversion and Pharmacokinetic Analysis of Trelagliptin in Beagle Dog Plasma by LC-MS/MS. (Pubmed Central) - Jun 25, 2020
In this study, no chiral bioconversion of (R)-trelagliptin to (S)-trelagliptin in beagle dog plasma was observed. The absolute bioavailability of (R)-trelagliptin was identified to be 128.2%.
- || Nesina (alogliptin) / Takeda, Zafatek (trelagliptin) / Takeda
Clinical, Journal: A Randomized Pilot Study of the Effect of Trelagliptin and Alogliptin on Glycemic Variability in Patients with Type 2 Diabetes. (Pubmed Central) - Jun 19, 2020
P4
The absolute bioavailability of (R)-trelagliptin was identified to be 128.2%. Once-weekly trelagliptin and once-daily alogliptin improved glycemic control and reduced GV without inducing hypoglycemia.
- | Retrospective data, Journal: Pancreatitis and pancreatic cancer in patientes treated with dipeptidyl peptidase-4 inhibitors: an extensive and updated meta-analysis of randomized controlled trials. (Pubmed Central) - May 29, 2020
available data do not support the hypothesis of an association of DPP4i treatment with pancreatitis. Present data do not suggest any association of DPP4i with pancreatic cancer, although they are insufficient to draw definitive conclusions.
- | Zafatek (trelagliptin) / Takeda
New P4 trial: Dose Modification Requirement for Trelagliptin in Egyptian Population (clinicaltrials.gov) - May 4, 2020
P4, N=6, Recruiting, Sponsor: British University In Egypt
- |||||| Zafatek (trelagliptin) / Takeda
Enrollment open, Trial completion date, Trial primary completion date, Monotherapy: Clinical Trial of Trelagliptin Succinate Tablets in the Treatment of Type 2 Diabetes (clinicaltrials.gov) - Apr 27, 2020
P3, N=240, Recruiting, Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Present data do not suggest any association of DPP4i with pancreatic cancer, although they are insufficient to draw definitive conclusions. Not yet recruiting --> Recruiting | Trial completion date: Feb 2020 --> Jul 2021 | Trial primary completion date: Jan 2020 --> Jun 2021
- | Marizev (omarigliptin) / Merck (MSD)
New trial: Omarigliptin in Four Healthy Egyptian Volunteers (clinicaltrials.gov) - Apr 27, 2020
P=N/A, N=4, Recruiting, Sponsor: British University In Egypt
- | Zafatek (trelagliptin) / Takeda, omarigliptin (MK-3102) / Merck (MSD)
Preclinical, Journal: Discovery of a Natural-Product-Derived Preclinical Candidate for Once-Weekly Treatment of Type 2 Diabetes. (Pubmed Central) - Apr 14, 2020
A single dose oral administration of 5 (3 mg/kg) inhibited >80% DPP-4 activity for more than 7 days in diabetic mice. The long-term antidiabetic efficacies of 5 (10 mg/kg, q.w) were better than the once-weekly trelagliptin and omarigliptin, especially in decreasing the hemoglobin A1c (HbA1c) level.
- ||| Zafatek (trelagliptin) / Takeda
Enrollment open: Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Severe Renal Impairment or End-stage Renal Disease" (clinicaltrials.gov) - Mar 29, 2020
P=N/A, N=100, Recruiting, Sponsor: Takeda
The long-term antidiabetic efficacies of 5 (10 mg/kg, q.w) were better than the once-weekly trelagliptin and omarigliptin, especially in decreasing the hemoglobin A1c (HbA1c) level. Not yet recruiting --> Recruiting
- || Nesina (alogliptin) / Takeda, Zafatek (trelagliptin) / Takeda
PK/PD data, Journal: An HPLC-MS/MS method for quantitation of trelagliptin and application in a comparative pharmacokinetic study. (Pubmed Central) - Mar 26, 2020
Discussion/ Compared with normal groups, the T1/2, apparent volume of distribution, area under the curve and bioavailability in model rats were significantly increased while the apparent plasma clearance decreased. The approach is proved to be straightforward and appropriate for quantitation of trelagliptin and application in pharmacokinetics studies.
- |||||| Zafatek (trelagliptin) / Takeda
New trial: Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Severe Renal Impairment or End-stage Renal Disease" (clinicaltrials.gov) - Feb 26, 2020
P, N=100, Not yet recruiting, Sponsor: Takeda
- || Zafatek (trelagliptin) / Takeda
Clinical, Journal: Changes in medication adherence and unused drugs after switching from daily dipeptidyl peptidase-4 inhibitors to once-weekly trelagliptin in patients with type 2 diabetes. (Pubmed Central) - Nov 14, 2019
Switching from daily DPP-4 inhibitors to once-weekly trelagliptin improved the satisfaction with the treatment, impression of the prescribed medicine and medication adherence in the type 2 diabetic patients who expresses a desire to reduce their prescription medicines. In such patients, improvements in the glycemic control and long-term prognosis might be expected through the reduction of unused drugs.
- | Journal: Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent. (Pubmed Central) - Oct 11, 2019
Sitagliptin, vildagliptin, saxagliptin & linagliptin showed antioxidant and neurorestorative effects in previous studies linked to DPP-4 inhibition...LC-MS/MS determination of once-weekly anti-diabetic DPP-4 inhibitors; omarigliptin & trelagliptin in plasma and brain tissue was employed after 2 h of oral administration to rats...A novel intranasal formulation was developed using sodium lauryl sulphate surfactant to solubilize the lipophilic omarigliptin with penetration enhancing & antimicrobial properties. Intranasal administration showed enhanced brain/plasma ratio by 3.3 folds compared to the oral group accompanied with 2.6 folds increase in brain glucagon-like peptide-1 concentration compared to the control group.
- | Zafatek (trelagliptin) / Takeda
Clinical, Journal, HEOR: Randomized Multicenter Evaluation of Quality of Life and Treatment Satisfaction in Type 2 Diabetes Patients Receiving Once-Weekly Trelagliptin Versus a Daily Dipeptidyl Peptidase-4 Inhibitor. (Pubmed Central) - Jun 21, 2019
P4
Once-weekly trelagliptin 100 mg administered for 12 weeks resulted in a numerically, but not statistically, greater improvement in QOL and treatment satisfaction versus daily DPP-4 inhibitors. The decision to administer once-weekly or daily DPP-4 inhibitor treatment is likely to depend on patient preferences and the treatment policies of physicians.
- |||||||||| Zafatek (trelagliptin) / Takeda
New P3 trial, Monotherapy: Clinical Trial of Trelagliptin Succinate Tablets in the Treatment of Type 2 Diabetes (clinicaltrials.gov) - May 6, 2019
P3, N=240, Not yet recruiting, Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- || Zafatek (trelagliptin) / Takeda
How and where can i buy Takeda's zafatek for type2 diabetes? Thank you (Twitter) - Mar 28, 2019
- || Zafatek (trelagliptin) / Takeda
Trial completion date, Trial primary completion date: Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus" (clinicaltrials.gov) - Jul 24, 2018
P=N/A, N=3000, Active, not recruiting, Sponsor: Takeda
The decision to administer once-weekly or daily DPP-4 inhibitor treatment is likely to depend on patient preferences and the treatment policies of physicians. Trial completion date: Apr 2021 --> Oct 2021 | Trial primary completion date: Apr 2021 --> Oct 2021
- ||| Zafatek (trelagliptin) / Takeda
New trial: Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus" (clinicaltrials.gov) - Jul 24, 2018
P=N/A, N=3000, Active, not recruiting, Sponsor: Takeda